Uriach reinforces its commitment within the natural and self-care products health segment and consolidates its business model in Europe. After a decade marked by a dozen acquisitions across the Old Continent, the Catalan pharmaceutical company closed the year 2025 with a 3% increase in sales, approaching the 500 million euros it had set as a goal when it launched its strategic plan in 2015. Although the improvement falls short of the figures recorded the previous year –revenue in 2024 increased by 54%–, the company acknowledges that the past year has been characterized by a "complex" context after several years of high-growth markets.

The arrival of the pandemic of covid-19 caught everyone off guard, but some people knew how to react better and faster than the rest and took the grand prize of providing the administrations with health material, the most precious good at a time of total shortage.